ClinicalTrials.gg
TerminatedNCT04780061Updated Sep 19, 2024Results posted

Dietary Supplements for COVID-19

A Phase 3 interventional study of Vitamin D3 50,000 IU and Vitamin C/Zinc in Covid19, sponsored by The Canadian College of Naturopathic Medicine. Terminated at 1 site in Canada. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-09-19.

Sponsored by The Canadian College of Naturopathic Medicine · Phase 3, Interventional, and Treatment

How we know

Why this study was terminated
Public PCR testing stopped in Ontario

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
90
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 17 studies testing cholecalciferol in COVID-19 — none open to participants now, 1 under way, 1 of them phase 3. Cholecalciferol · COVID-19.

Enrollment
8th of 17
90 · median 80
Started
2021
with 3 others
Phase 3
5 of 17
none open now
Registered
10th of 17
by date

Among the 17 studies testing cholecalciferol in COVID-19, this one is the 8th largest by enrollment, is one of 4 that started in 2021, is one of 5 in phase 3, and was the 10th registered.

COVID-19

7,996 studies on the registry are indexed under COVID-19; 469 are open to participants now.

Browse COVID-19 studies →

Open to participants now

None of the 17 studies testing cholecalciferol in COVID-19 is open now. The open studies under COVID-19, anywhere →

About cholecalciferol

Cholecalciferol: first FDA approval 2000 (INFUVITE ADULT), first EMA approval 2005. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 356 COVID-19 studies recruiting now, 205 (58%) set no upper age limit and 84 (24%) stop at 75 or younger; 90 take children under 18; 135 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 17 studies testing cholecalciferol in COVID-19 as a file.
02

Study summary

This is a double blind, placebo controlled, phase III randomized controlled trial evaluating the effects of the dietary supplements vitamin C, vitamin D, vitamin K, and zinc versus placebo on the overall health, symptom severity, and symptom duration of outpatients diagnosed with SARS-CoV-2.

Read the detailed description

This study proposed is a double-blind, placebo-controlled, phase III randomized controlled trial powered to detect meaningful differences in the overall health and symptom severity of people with COVID-19 between the treatment and control arms. Eligible participants will be randomly assigned, using a web randomization system, in a ratio of 1:1 to one of the following groups: (1) nutrient therapy with vitamin D, vitamin C, vitamin K2, and zinc or (2) placebo. Total trial duration will be 12 weeks. Nutrients or placebo will be given for a period of 21 days following enrolment and randomization. Total trial duration will be 12 weeks. Adverse events will be collected during the treatment phase plus one additional week (maximum 4 weeks).

With respect to the primary outcome of participant-reported overall health, power calculations were conducted based on between-group differences at a single time point (21 days) and Cohen's guideline for a small effect size of 0.3. A sample size of 176 (88 per arm) provides 80% power to detect a difference at an α of 0.05. To account for an approximate 10-15% lost to follow-up we will enrol 200 participants (100 per arm).

03

Conditions studied

  • Covid19

Browse trials for

Keywords

  • Natural Health Products
  • NHP
  • Dietary Supplements
  • Vitamin C
  • Vitamin D
  • Vitamin K
  • Zinc
  • COVID-19
  • SARS-CoV-2
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Adults (≥18) who test positive for SARS-CoV-2 in an outpatient setting
  2. Access to internet

Exclusion criteria

Exclusion Criteria:

  1. Symptom onset greater than 4 days prior to enrolment
  2. Supplementing regularly with >500 mg vitamin C, >1000 units vitamin D, >120 mcg vitamin K (any form), or >15 mg zinc taken daily within the past month
  3. Currently taking warfarin or an equivalent vitamin K antagonist anticoagulant
  4. End stage chronic kidney disease
  5. History of calcium oxalate kidney stones
  6. Active granulomatosis (sarcoidosis, tuberculosis, lymphoma)
  7. Known hypercalcemia or hypervitaminosis D
  8. Currently taking either of the following antibiotics: cephalexin, tetracyclines
  9. Participating in an study or participation in an investigational study within the past 30 days
  10. Any reason which, under the discretion of the qualified investigator or delegate, would preclude the patient from participating.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
90 participants (actual)

Study arms

  • Experimental
    Treatment

    Specific Product: Vitamin D3 50,000 IU Formulation: Capsule. Each capsule will contain 500 mg (50,000 units) cholecalciferol (vitamin D3) Dose: One capsule on day 1 of the intervention period Specific Product: Vitamin K2/D Formulation: Liquid. Each 0.0285 mL drop contains 30 mcg menaquinone-7 (MK-7, vitamin K2) and 3.125 mcg (125 units) cholecalciferol (vitamin D3). Dose: 0.114 mL (four drops) twice daily for 21 days totalling 240mcg MK-7 and 1,000 units cholecalciferol per day. Specific Product: Vitamin C/Zinc Formulation: Capsule. Each capsule will contain 666 mg ascorbic acid (vitamin C) and 8.3 mg of zinc acetate Dose: Three capsules three times daily for 21 days totalling 6 g ascorbic acid and 75 mg zinc acetate per day.

    Drug: Vitamin D3 50,000 IU · Dietary Supplement: Vitamin C/Zinc · Dietary Supplement: Vitamin K2/D

  • Placebo comparator
    Control

    Specific Product: Vitamin D3 50,000 IU Placebo Equivalent: microcrystalline cellulose capsule, 350 mg Specific Product: Vitamin K2/D Placebo Equivalent: Medium chain triglyceride oil Specific Product: Vitamin C/Zinc Placebo Equivalent: microcrystalline cellulose capsule, 350 mg

    Other: Microcrystalline Cellulose Capsule · Other: Medium Chain Triglyceride Oil

Interventions

  • DrugCholecalciferolStudies of CholecalciferolCholecalciferol pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    This is a loading dose of Vitamin D. Vitamin D (cholecalciferol \[vitamin D3\]) is a fat-soluble vitamin that is synthesized following ultraviolet radiation to the skin, naturally occurs in a few dietary sources and is available as a dietary supplement.

    Also known as: Cholecalciferol

  • Dietary supplementVitamin C/Zinc

    Drug pages: Ascorbic AcidStudies of Ascorbic AcidAscorbic Acid pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · ZincStudies of ZincZinc pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    This is a combination of Vitamin C and Zinc. Vitamin C (ascorbic acid, ascorbate) is a water-soluble vitamin that naturally occurs in many foods and is sold as a dietary supplement. It is required for the functioning of several enzymes and is important for the immune system. Zinc is one of the most abundant essential trace elements in the human body and is required for the function of several hundred enzymes and transcription factors.

  • Dietary supplementVitamin K2/D

    Drug page: Vitamin K 2Studies of Vitamin K 2Vitamin K 2 pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    This is a combination of Vitamin K2 (menaquinone-7) and vitamin D. Vitamin K (menaquinone-7 \[vitamin K2\]) is a fat-soluble vitamin found in foods and sold as a dietary supplement. Vitamin K plays a large role in synthesizing coagulation factors in the blood, and vitamin K deficiency has been associated with uncontrolled bleeding. Vitamin K1 (phylloquinone) is an alternate form of vitamin K found in foods and supplements; however, vitamin K2 has a better absorption profile50 and additionally plays a role in bone metabolism controlling the binding of calcium, especially in older adults, where it attenuates the rate of bone loss

  • OtherMicrocrystalline Cellulose Capsule

    Placebo equivalent of Vitamin C/Zinc and Vitamin D3.

  • OtherMedium Chain Triglyceride Oil

    Placebo equivalent of Vitamin K2/D

06

What researchers measure

Primary outcomes

  1. Participant-reported Overall Health

    Measured using the EuroQol Visual Assessment Scale (EQ-VAS). Scores each day range from 0 (worst health imaginable) and 100 (best health imaginable). Scores summed over a 21-day period for a total range of 0-2100.

    Time frame: During the intervention period (Daily for 21 days)

Secondary outcomes

  1. Effect of COVID-19 on the Health Status of Participants

    Measured using the EuroQol 5-Dimension 5-Level (EQ-5D-5L) questionnaire. Scores are converted into a unique health state. Health states are converted to an index value between 0 and 1, where 1 is considered the best possible health and 0 is the worst possible health.

    Time frame: Baseline plus weeks 1, 2, 3, 4, 8, and 12

  2. Symptom Severity of Common COVID-19 Symptoms

    Measured using an internally-developed questionnaire. Includes fever, cough, shortness of breath, fatigue, headache, myalgia/arthralgia, nausea, vomiting, diarrhea, congestion, loss of taste, and loss of smell. Scores range from 0-3 for each symptom, totaling 0-42 for each day. 0 = no symptom, 1 = mild symptom, 2 = moderate symptom, 3 = severe symptom. Scores converted into a number out of 100 and summed over 21 days for a range of 0-2100 where a higher score indicates a higher symptom severity (i.e., a worse outcome).

    Time frame: During the intervention period (Daily for 21 days)

  3. Total Symptom Duration

    Measured as the time to a complete reduction of symptoms with no relapses (i.e., a 0 in all categories on the symptom questionnaire).

    Time frame: During the intervention period (21 days)

  4. Incidence of Delayed Return to Usual Health

    Measured by the number of people experiencing "ongoing symptomatic COVID-19" (symptoms persisting between 4 and 12 weeks) and the number of people experiencing "post-COVID-19 syndrome" (symptoms persisting at least 12 weeks)

    Time frame: 12 weeks

  5. Number of Participants With a Hospital Visit or Admission

    Includes ER visits, acute care admissions, and ICU admissions

    Time frame: 12 weeks

07

Results

Posted Sep 19, 2024
Limitations and caveats
Early termination leading to small number of subjects analyzed; Symptom severity and duration questionnaire not validated

Participant flow

Participants were enrolled from outpatient COVID-19 test centres associated with The Ottawa Hospital. The primary site for enrolment and coordination of the study was The Centre for Health Innovation, Ottawa, Canada with support from the Ottawa Hospital Research Institute.

Participant flow — Overall Study
MilestoneTreatmentControl
Started4446
Treated4244
Completed3631
Not completed815
Withdrew: Withdrawal by subject58
Withdrew: Adverse event22
Withdrew: Lost to follow-up15

Outcome measures

PrimaryParticipant-reported Overall Health

Measured using the EuroQol Visual Assessment Scale (EQ-VAS). Scores each day range from 0 (worst health imaginable) and 100 (best health imaginable). Scores summed over a 21-day period for a total range of 0-2100.

Time frame:
During the intervention period (Daily for 21 days)
Reported as:
Mean · score on a scale
Participant-reported Overall Health
score on a scaleTreatmentControl
Participant-reported Overall Health1790 ± 226.61752.6 ± 220.7
Statistical analysis
  • Treatment vs Control · t-test, 2 sided · p = 0.53
SecondaryEffect of COVID-19 on the Health Status of Participants

Measured using the EuroQol 5-Dimension 5-Level (EQ-5D-5L) questionnaire. Scores are converted into a unique health state. Health states are converted to an index value between 0 and 1, where 1 is considered the best possible health and 0 is the worst possible health.

Time frame:
Baseline plus weeks 1, 2, 3, 4, 8, and 12
Reported as:
Mean · score on a scale
Effect of COVID-19 on the Health Status of Participants
score on a scaleTreatmentControl
Baseline0.88 ± 0.10.88 ± 0.12
Week 10.95 ± 0.080.93 ± 0.1
Week 20.95 ± 0.070.94 ± 0.09
Week 30.94 ± 0.080.91 ± 0.1
Week 40.96 ± 0.080.97 ± 0.05
Week 80.95 ± 0.080.95 ± 0.09
Week 120.96 ± 0.070.96 ± 0.07
SecondarySymptom Severity of Common COVID-19 Symptoms

Measured using an internally-developed questionnaire. Includes fever, cough, shortness of breath, fatigue, headache, myalgia/arthralgia, nausea, vomiting, diarrhea, congestion, loss of taste, and loss of smell. Scores range from 0-3 for each symptom, totaling 0-42 for each day. 0 = no symptom, 1 = mild symptom, 2 = moderate symptom, 3 = severe symptom. Scores converted into a number out of 100 and summed over 21 days for a range of 0-2100 where a higher score indicates a higher symptom severity (i.e., a worse outcome).

Time frame:
During the intervention period (Daily for 21 days)
Reported as:
Mean · score on a scale
Symptom Severity of Common COVID-19 Symptoms
score on a scaleTreatmentControl
Symptom Severity of Common COVID-19 Symptoms166.3 ± 92.3192.9 ± 153.6
Statistical analysis
  • Treatment vs Control · t-test, 2 sided · p = 0.09
SecondaryTotal Symptom Duration

Measured as the time to a complete reduction of symptoms with no relapses (i.e., a 0 in all categories on the symptom questionnaire).

Time frame:
During the intervention period (21 days)
Reported as:
Median · Days
Total Symptom Duration
DaysTreatmentControl
Total Symptom Duration13.0 (0 to 21)12.5 (0 to 21)
Statistical analysis
  • Treatment vs Control · Log Rank · p = 0.81
SecondaryIncidence of Delayed Return to Usual Health

Measured by the number of people experiencing "ongoing symptomatic COVID-19" (symptoms persisting between 4 and 12 weeks) and the number of people experiencing "post-COVID-19 syndrome" (symptoms persisting at least 12 weeks)

Time frame:
12 weeks
Reported as:
Count of participants · Participants
Incidence of Delayed Return to Usual Health
ParticipantsTreatmentControl
Ongoing Symptomatic COVID-1965
Post COVID-19 Syndrome33
SecondaryNumber of Participants With a Hospital Visit or Admission

Includes ER visits, acute care admissions, and ICU admissions

Time frame:
12 weeks
Reported as:
Count of participants · Participants
Number of Participants With a Hospital Visit or Admission
ParticipantsTreatmentControl
Emergency Room Visits24
Acute Care Admissions00
Intensive Care Unit Admissions00

Adverse events

Collected over During the intervention period (21 days) plus 1 additional week (4 weeks total). Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Treatment0/44 (0%)0/44 (0%)16/44 (36.4%)
Control0/46 (0%)1/46 (2.2%)6/46 (13%)
Most frequent serious events
Most frequent serious events
EventTreatmentControl
Ectopic PregnancyPregnancy, puerperium and perinatal conditions0/441/46
Most frequent other events
Most frequent other events
EventTreatmentControl
NauseaGastrointestinal disorders8/441/46
Abdominal PainGastrointestinal disorders2/442/46
BloatingGastrointestinal disorders2/440/46
HeartburnGastrointestinal disorders1/440/46
Jaw PainMusculoskeletal and connective tissue disorders1/440/46
DyspepsiaGastrointestinal disorders1/440/46
EpistaxisRespiratory, thoracic and mediastinal disorders1/440/46
HeadacheNervous system disorders0/441/46
VomitingGastrointestinal disorders0/441/46
DiarrheaGastrointestinal disorders0/441/46

Baseline characteristics

Participants only included if they began study treatments.

Age, Continuous
Age, Continuous(years)TreatmentControlTotal
Mean38 ± 12.739.9 ± 14.938.9 ± 13.8
Sex: Female, Male
Sex: Female, Male(Participants)TreatmentControlTotal
Female172643
Male251843
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)TreatmentControlTotal
Black123
White373471
Latin American101
Asian (South)011
Asian (Southeast)112
Asian (East)022
Middle Eastern202
Vaccination Status
Vaccination Status(Participants)TreatmentControlTotal
Received First Dose414283
Received Second Dose414283
Received Third Dose373067
Unvaccinated123
Comorbidities
Comorbidities(Participants)TreatmentControlTotal
Hypertension314
Diabetes022
Coronary Artery Disease000
Asthma7916
Chronic Kidney Disease000
Chronic Obstructive Pulmonary Disorder022
Liver Disease000
Cancer011
Immunodeficiency000
Other Variables
Other Variables(Participants)TreatmentControlTotal
Smoking History7815
Symptoms at Testing383674
08

Study locations

1 site
  • The Centre for Health Innovation
    Ottawa, Ontario K2P0M7, Canada
09

References and documents

Publications

  • Legacy M, Seely D, Conte E, Psihogios A, Ramsay T, Fergusson DA, Kanji S, Simmons JG, Wilson K. Dietary supplements to reduce symptom severity and duration in people with SARS-CoV-2: study protocol for a randomised, double-blind, placebo controlled clinical trial. BMJ Open. 2022 Mar 3;12(3):e057024. doi: 10.1136/bmjopen-2021-057024. PubMed 35241474 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2021 to primary completion in May 2022, 9 months.

Results were first posted in Sep 2024, 2 years 4 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 1, 2021
First posted
Mar 3, 2021
StartActual
Jul 12, 2021
Primary completionActual
May 3, 2022
CompletionActual
Jul 7, 2022
Results first posted
Sep 19, 2024
Last update
Sep 19, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 19, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04780061
Lead sponsor
The Canadian College of Naturopathic Medicine
Collaborators
Ottawa Hospital Research Institute, Vitazan Professional, New Roots Herbal
Responsible party
Sponsor
First posted
Mar 3, 2021
Start date
Jul 12, 2021
Primary completion
May 3, 2022
Completion
Jul 7, 2022
Results posted
Sep 19, 2024
Last update
Sep 19, 2024

Study contacts

Dugald Seely, ND, MSc
principal investigator · Canadian College of Naturopathic Medicine
Kumanan Wilson, MD, MSc
principal investigator · The Ottawa Hospital Research Institute

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Sep 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Cholecalciferol · Ascorbic Acid · Zinc · Vitamin K 2

Start the discussion